Skip to main content

Table 3 The results of base-case analysis at the 10-year horizon

From: Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective

Parameters

Sin-Che group

Pla-Che group

Costs ($)

  

PFS state

20632.57

9593.25

PD state

11066.64

11094.17

Total Cost

31699.21

20,687.42

Incremental costs ($)

11011.80

 

Effectiveness (QALYs)

  

PFS state

0.53

0.31

PD state

0.21

0.22

Total effectiveness

0.74

0.53

Incremental effectiveness (QALYs)

0.21

 

ICER ($/QALY)

51908.20

Â